Revolution Medicines Inc
RVMD
NASDAQ
Biotechnology
$203.71
USD
+1.71 (+0.85%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $43.21B
Volume 784.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-1.77B
TTM
-117.8%
YoY
Operating Cash Flow
$-1.22B
TTM
-78.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 40.6 | 52.8 | 66.7 | 101.3 | 110.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 264.7 | 315.3 | 361.6 | 445.2 | 505.1 |
Operating Income | -264.7 | -315.3 | -361.6 | -445.2 | -505.1 |
EBITDA | -262.7 | -312.9 | -359.3 | -442.9 | -502.7 |
Other Income / Expense | -4.6 | -0.6 | -12.6 | -15.9 | -151.0 |
Total Other Income / Expense | 16.9 | 10.1 | -3.3 | -8.6 | -139.2 |
Income Before Income Taxes | -247.8 | -305.2 | -364.9 | -453.8 | -644.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -247.8 | -305.2 | -364.9 | -453.8 | -644.4 |
Consolidated Net Income / Loss | -247.8 | -305.2 | -364.9 | -453.8 | -644.4 |
Net Income Attributable to Common Shareholders | -247.8 | -305.2 | -364.9 | -453.8 | -644.4 |
Basic EPS | -$1.31 | -$1.61 | -$1.88 | -$2.29 | -$3.06 |
Diluted EPS | -$1.31 | -$1.61 | -$1.88 | -$2.29 | -$3.06 |
Basic Shares Outstanding | 188.6M | 189.2M | 194.6M | 198.1M | 210.9M |
Diluted Shares Outstanding | 188.6M | 189.2M | 194.6M | 198.1M | 210.9M |